Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard

Poorly biodegradable, incomplete Freund’s adjuvant (IFA)-based anticancer vaccines primed CD8(+) T cells that did not localize to the tumor site but to the persisting, antigen-rich vaccination site, which became a T-cell graveyard. Short-lived, water-based formulations and the provision of immunosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hailemichael, Yared, Overwijk, Willem W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782014/
https://www.ncbi.nlm.nih.gov/pubmed/24073366
http://dx.doi.org/10.4161/onci.24743
_version_ 1782285507049291776
author Hailemichael, Yared
Overwijk, Willem W
author_facet Hailemichael, Yared
Overwijk, Willem W
author_sort Hailemichael, Yared
collection PubMed
description Poorly biodegradable, incomplete Freund’s adjuvant (IFA)-based anticancer vaccines primed CD8(+) T cells that did not localize to the tumor site but to the persisting, antigen-rich vaccination site, which became a T-cell graveyard. Short-lived, water-based formulations and the provision of immunostimulatory molecules overcame this issue, resulting in tumor suppression. Here, we discuss the implications of these findings for the development of therapeutic anticancer vaccines.
format Online
Article
Text
id pubmed-3782014
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37820142013-09-26 Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard Hailemichael, Yared Overwijk, Willem W Oncoimmunology Author's View Poorly biodegradable, incomplete Freund’s adjuvant (IFA)-based anticancer vaccines primed CD8(+) T cells that did not localize to the tumor site but to the persisting, antigen-rich vaccination site, which became a T-cell graveyard. Short-lived, water-based formulations and the provision of immunostimulatory molecules overcame this issue, resulting in tumor suppression. Here, we discuss the implications of these findings for the development of therapeutic anticancer vaccines. Landes Bioscience 2013-07-01 2013-04-30 /pmc/articles/PMC3782014/ /pubmed/24073366 http://dx.doi.org/10.4161/onci.24743 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Hailemichael, Yared
Overwijk, Willem W
Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
title Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
title_full Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
title_fullStr Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
title_full_unstemmed Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
title_short Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
title_sort peptide-based anticancer vaccines: the making and unmaking of a t-cell graveyard
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782014/
https://www.ncbi.nlm.nih.gov/pubmed/24073366
http://dx.doi.org/10.4161/onci.24743
work_keys_str_mv AT hailemichaelyared peptidebasedanticancervaccinesthemakingandunmakingofatcellgraveyard
AT overwijkwillemw peptidebasedanticancervaccinesthemakingandunmakingofatcellgraveyard

Ejemplares similares